Circulating Tumor DNA Panel – Colorectal / Lung / Breast
Discover the accelerated NGS with Reliable result for variant with ultra low VAF
Overview
Circulating Tumor DNA Panel for Colorectal / Lung / Breast Cancer
The detection sensitivity for low-frequency variants from sample with limited yield is of great importance to a ctDNA analysis kit.
Celemics has developed NGS ctDNA-based kits for colon, breast, and lung cancer assays through collaborative research with Seoul National University Hospital since 2017. We have integrated our market-leading proprietary technologies including hybridization probe design algorithms, noise removal techniques, and reagent optimization. The panel is thoroughly validated and ready-to-use for clinical diagnostics.
Highly Optimized Panel for Clinical Testing with Exceptional Accuracy
This is a complete performance validated panel, conducted with actual clinical patient samples through collaborative research with Seoul National University Hospital. Through the extensive validation studies, Celemics’ ctDNA panel verified assessment of 15 key genes for colorectal cancer, 27 for breast cancer, 28 for lung cancer.
| Colorectal Cancer | ||
|---|---|---|
| Sensitivity | Freq. 0.5% | 100% |
| Freq. 1.0% | 100% | |
| Specificity | 97.9% | |
| Breast Cancer | ||
|---|---|---|
| Sensitivity | Freq. 0.5% | 94.4% |
| Freq. 1.0% | 100% | |
| Specificity | 96.3% | |
| Lung Cancer | ||
|---|---|---|
| Sensitivity | Freq. 0.5% | 100% |
| Freq. 1.0% | 100% | |
| Specificity | 100% | |
Robust BI with Unique Molecular Identifiers(UMI) for ultra-low VAF detection
Receive high-quality data supported by Celemics proprietary
UMI algorithms and Bioinformatics software, enabling effective detection of ultra-low VAF by efficiently removing duplicates and generating consensus read, which will result in increased sequencing efficiency
Along with exclusive barcodes, Celemics also provides
our own-designed modular software allows seamless integration of Bioinformatics solution, from FASTQ to clinical report.
Proven variant detection performance even with low-yield challenging clinical sample
Detection sensitivity and specificity of ctDNA panels have been tested and verified with various actual clinical specimen.
Even with the template DNA amount as low as 10 ng, the panel demonstrated market-leading performance with superior sensitivity and specificity and these panels been supported by numerous peer review publications.
Exclusive Bioinformatics algorithms for accurate analysis
Celemics applies algorithms for eliminating the sequencing error and reducing noise to increase the detection sensitivity and specificity. By applying these exclusive pipeline features, we can provide accurate and reliable sequencing results to our customers.
We continuously monitor and improve of the noise removal technology by data accumulation
Simple workflow of circulating tumor DNA panel
- Able to assess ctDNA with ultra-low variant allele frequency (VAF)
- Simple workflow and easy-to-follow protocol
- Modular algorithm to be applied in the existing pipeline.
- Retrieves more unique reads than that from conventional duplication removal algorithms, reducing sequencing costs
- Noise removal and accurate calls due to proprietary consensus sequence generation algorithm
Bioinformatics SW for Noise Reduction and Duplicate Read Recovery
- Minimizes the noise for accurate analysis of variants with ultra-low VAF from ctDNA
- Generates consensus read to support noise suppression
- Continuous improvement of the noise removal technology by data accumulation
Specification
| Colorectal Cancer | Breast Cancer | Lung Cancer | |
|---|---|---|---|
| Gene count* | 15 genes | 27 genes | 28 genes |
| Covered region | Whole CDS | Whole CDS (8 genes)
Hotspot exonic region (20 genes) |
|
| Target size | 49 kb | 99 kb | 47 kb |
| Mutation type | SNV, Indel | ||
| Sample type (amount) | Plasma (>20 ng of cfDNA) | ||
| Platform | All sequencers from illumina | ||
| Bioinformatics pipeline |
1. Primary and Secondary analysis result (FASTQ to VCF) 2. Secondary Analysis: CNV, Large InDel 3. Tertiary Analysis: Clinical interpretation * Linux-based consensus read generation software |
||
Specification - Gene List
- 15 genes | Gene count
- 49 kb | Target Size
- Whole CDS | Target Region
| ctDNA Colorectal Cancer Panel | APC | ATM | BRAF | EGFR | ERBB2 | FBXW7 | KRAS | MET |
|---|---|---|---|---|---|---|---|---|
| NRAS | PDGFRA | PIK3CA | PTEN | SMAD4 | TCF7L2 | TP53 |
- 27 genes | Gene count
- 99 kb | Target Size
- Whole CDS | Target Region
| ctDNA Breast Cancer Panel |
AKT1 | APC | AR | BRCA1 | BRCA2 | CCND1 | CDH1 | EGFR |
|---|---|---|---|---|---|---|---|---|
| ERBB2 | ESR1 | FGFR1 | FGFR2 | GATA3 | IGF1R | KIT | KRAS | |
| MAP2K4 | MAP3K1 | MDM2 | MYC | NF1 | PIK3CA | PIK3R1 | PTEN | |
| RB1 | TOP2A | TP53 |
- 28 genes | Gene count
- 47 kb | Target Size
- Whole CDS for 8 genes and Hotspot exonic region for 20 genes, 3 Intronic regions | Target Region
| ctDNA Lung Cancer Panel |
AKT1 | ALK | ARAF | ARID1A | BRAF | CBL | CDKN2A | EGFR |
|---|---|---|---|---|---|---|---|---|
| ERBB2 | HRAS | KEAP1 | KRAS | MAP2K1 | MET | MTOR | NF1 | |
| NRAS | NTRK1 | NTRK2 | PIK3CA | PTEN | RB1 | RIT1 | ROS1 | |
| SETD2 | STK11 | TP53 | U2AF1 |
Related Products
Highly optimized, user- convenient NGS library preparation kit for all Celemics panels
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Incomparable quality magnetic bead for simple, flexible, and reproducible purification
Market-leading yield and accuracy with minimized PCR bias. Includes all reaction components for PCR
Highly optimized, user- convenient NGS library preparation kit for all Celemics panels
End-to-end complete Bioinformatics solution; Trust CAS with your BI analysis
Incomparable quality magnetic bead for simple, flexible, and reproducible purification
Market-leading yield and accuracy with minimized PCR bias. Includes all reaction components for PCR
Resources
Technical Resources
Safety Data Sheets
If you require the latest MSDS file, please contact us via ‘Contact Us‘.
MSDS_Liquid Biopsy Panel_Illumina
MSDS_Liquid Biopsy Panel_Thermo Fisher
MSDS_Liquid Biopsy Panel_MGI
References
Cancer Research and Treatment
Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: A Multicenter Phase Ib/II Study (K-MASTER-13)
Koo DH, Jung M, Kim YH, Jeung HC, Zang DY, Bae WK, Kim H, Kim HS, Lee CK, Kwon WS, Chung HC. Varlitinib and Paclitaxel for EGFR/HER2 Co-Expressing Advanced Gastric Cancer: a Multicenter Phase Ib/II Study (K-MASTER-13). Cancer Research and Treatment. 2024 Apr 29.
10.4143/crt.2023.1324
Annals of Laboratory Medicine
Identification of potential genomic alterations using pan-cancer cell-free DNA next-generation sequencing in patients with gastric cancer
Kim B, Kim Y, Cho JY, Lee KA. Identification of potential genomic alterations using pan-cancer cell-free DNA next-generation sequencing in patients with gastric cancer. Annals of laboratory medicine. 2024 Mar 1;44(2):164-73.
10.3343/alm.2023.0187
Cancers
Discovery and Validation of Survival-Specific Genes in Papillary Renal Cell Carcinoma Using a Customized Next-Generation Sequencing Gene Panel
Hwang J, Bang S, Choi MH, Hong SH, Kim SW, Lee HE, Yang JH, Park US, Choi YJ. Discovery and Validation of Survival-Specific Genes in Papillary Renal Cell Carcinoma Using a Customized Next-Generation Sequencing Gene Panel. Cancers. 2024 Jan;16(11):2006.
10.3390/cancers16112006
Frontiers in Neurology
Case report: Compound heterozygous variants detected by next-generation sequencing in a Tunisian child with ataxia-telangiectasia
Ammous-Boukhris N, Abdelmaksoud-Dammak R, Ben Ayed-Guerfali D, Guidara S, Jallouli O, Kamoun H, Charfi Triki C, Mokdad-Gargouri R. Case report: Compound heterozygous variants detected by next-generation sequencing in a Tunisian child with ataxia-telangiectasia. Frontiers in Neurology. 2024 May 31;15:1344018.
10.3389/fneur.2024.1344018